How to Get Repatha in Colorado

What Is Repatha and Why Colorado Patients Need It

Evolocumab (Repatha) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more LDL receptors available, which pulls more LDL-C out of circulation. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy. [1]

Familial hypercholesterolemia affects roughly 1 in 250 people in the general population. [2] In Colorado, that translates to an estimated 23,000 to 25,000 residents who may qualify for a PCSK9 inhibitor. Many remain undiagnosed or under-treated despite having LDL-C levels above 190 mg/dL on statin therapy. The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol identifies a PCSK9 inhibitor as a reasonable addition when LDL-C remains at or above 70 mg/dL in very-high-risk ASCVD patients despite maximally tolerated statin plus ezetimibe. [3]

Because Repatha costs approximately $500 to $600 per month at list price, access almost always depends on insurance coverage, prior authorization, or Amgen's patient assistance program. Getting the prescription written is only the first step.

Who Can Prescribe Repatha in Colorado

Any licensed prescriber in Colorado can write a Repatha prescription. That means physicians (MD, DO), nurse practitioners (NPs), and physician assistants (PAs) all have prescriptive authority for evolocumab under Colorado law. [4] NPs in Colorado hold full practice authority, meaning no physician collaboration agreement is required for an NP to prescribe Repatha independently.

For telehealth, Colorado follows the "same standard of care" rule. A provider conducting a synchronous audio-video visit with a Colorado-licensed prescriber can legally issue a Repatha prescription if the clinical evaluation is sufficient to establish the indication. Asynchronous-only visits (text or photo review without a live encounter) carry more legal ambiguity for a new prescription of a specialty medication like evolocumab, so most telehealth platforms use synchronous video for the initial consult.

Specialists who most commonly prescribe Repatha include cardiologists, lipidologists, and endocrinologists. Primary care physicians and internists prescribe it as well, though some prefer to co-manage with a specialist when LDL-C levels are severely elevated (above 300 mg/dL), which can suggest HoFH. [5]

Labs and Clinical Workup Required Before a Repatha Prescription

A lipid panel is the minimum lab requirement before a Colorado provider will prescribe evolocumab. Most will also want a complete metabolic panel (CMP) to assess liver and kidney function, and a thyroid-stimulating hormone (TSH) level to rule out hypothyroidism as a correctable cause of hypercholesterolemia. [6]

Specific values insurers and guidelines look for:

• LDL-C at or above 70 mg/dL in very-high-risk ASCVD patients despite maximally tolerated statin plus ezetimibe. [3]
• LDL-C at or above 100 mg/dL in high-risk ASCVD patients on maximal statin therapy.
• LDL-C at or above 190 mg/dL in patients with probable or confirmed FH, with or without ASCVD.

Documentation of prior statin use, statin intolerance, and ezetimibe trial is nearly always required for prior authorization. Labs should generally be drawn within 90 days of the PA submission. Some Colorado commercial plans (including Anthem BCBS Colorado and Cigna Colorado plans) require labs within 60 days, so check your plan's specific criteria before scheduling labs.

A cardiovascular risk assessment using the Pooled Cohort Equations or a coronary artery calcium (CAC) score may strengthen the clinical case when LDL-C is borderline. The 2018 AHA/ACC guideline states that a CAC score of 100 or above "favors initiation" of more intensive lipid-lowering therapy. [3]

The FOURIER Trial: Why This Drug Gets Prescribed

The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) enrolled 27,564 patients with established ASCVD and LDL-C at or above 70 mg/dL on optimized statin therapy. Participants were randomized to evolocumab 140 mg every 2 weeks or 420 mg monthly versus placebo. [7]

At a median follow-up of 2.2 years, evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL to 30 mg/dL. The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of the evolocumab group versus 11.3% of the placebo group, a relative risk reduction of 15% (P<0.001). The key secondary endpoint (cardiovascular death, MI, or stroke) showed a 20% relative risk reduction (P<0.001). [7]

Rates of adverse events were similar between groups. Injection-site reactions occurred in 2.1% of evolocumab-treated patients versus 1.6% of placebo patients. No meaningful increase in neurocognitive adverse events was detected. [7]

These data form the backbone of every prior authorization request for Repatha in an ASCVD indication. Insurers expect to see documentation that the patient mirrors the FOURIER inclusion criteria.

How to Get a Repatha Prescription in Colorado: Step-by-Step

Getting Repatha prescribed and delivered involves four sequential steps. Missing any one of them delays access by days to weeks.

Step 1: Establish the clinical indication. Schedule a visit with your Colorado-licensed prescriber, either in person or via a telehealth platform. Bring your most recent lipid panel (ideally within 90 days), a list of current and past statin medications, and documentation of any statin side effects. If you have a history of MI, stroke, coronary artery bypass graft, or percutaneous coronary intervention, bring those records as well.

Step 2: Confirm prior authorization requirements. Your prescriber's office or the telehealth platform's care coordination team will contact your insurer to verify coverage and obtain the specific prior authorization (PA) criteria. For Colorado commercial plans, typical PA requirements include: confirmed ASCVD or FH diagnosis, documentation of maximally tolerated statin therapy (usually two separate statins at different doses), documentation of ezetimibe 10 mg daily (or documented intolerance), and a qualifying LDL-C on that background therapy. [8]

Step 3: Submit the PA and appeal if denied. First-time PA requests for Repatha are denied at relatively high rates, around 50 to 60% on initial submission, according to analysis of specialty pharmacy data. Most denials are overturned on first appeal when the clinician submits a letter of medical necessity that directly addresses the insurer's criteria using the FOURIER outcome data and the 2018 AHA/ACC guideline language. [9] An experienced prescriber or a specialty pharmacy's PA support team can reduce the time from submission to approval to 5 to 10 business days.

Step 4: Fill at a specialty pharmacy. Repatha is distributed through specialty pharmacies, not standard retail chains. Amgen's preferred specialty pharmacy network includes CVS Specialty, Walgreens Specialty, and Accredo, all of which serve Colorado. Once the PA is approved, most patients receive their first shipment within 3 to 7 business days. The medication ships cold (2 to 8 degrees Celsius) and should be stored in the refrigerator.

Telehealth Repatha Prescribing in Colorado

Colorado is a full-practice telehealth state for prescribing. A Colorado-licensed NP, PA, or physician can evaluate a patient over synchronous video, establish the indication, and transmit an electronic prescription to a specialty pharmacy in a single visit. [4]

Most telehealth platforms that manage lipid disorders in Colorado follow this workflow: an online intake form collects your medical history and medication list, you upload recent labs, a provider reviews the intake and schedules a video visit, and the prescription is transmitted directly to your specialty pharmacy of choice after the visit. The entire process from account creation to prescription transmission can take as little as 48 to 72 hours if your labs are current.

Telehealth prescribing for Repatha does not reduce the prior authorization burden. The same insurer criteria apply regardless of whether the prescription comes from a brick-and-mortar cardiologist or an online provider. What telehealth does reduce is the access barrier for Colorado patients in rural counties such as Chaffee, Custer, Mineral, or San Juan, where no lipidologist or cardiologist practices within 60 miles.

The Colorado Medical Board confirmed in 2022 guidance that telehealth prescribing for chronic disease management meets the same standard of care as in-person care when a live synchronous audio-video encounter is used and the prescriber holds an active Colorado license. [4]

Colorado Medicaid and Commercial Insurance Coverage

Colorado Medicaid (Health First Colorado) does not currently cover Repatha for familial hypercholesterolemia or established ASCVD as a standalone indication. The state's Preferred Drug List places evolocumab in a non-covered tier for those indications. Coverage is available only when the indication is linked to a type 2 diabetes diagnosis under specific managed care plan formularies. This is a significant coverage gap affecting roughly 8,000 to 10,000 Colorado Medicaid enrollees who may have FH or ASCVD without diabetes. [10]

For commercial insurance, most Colorado plans cover Repatha under the specialty drug tier (Tier 4 or Tier 5), with monthly patient cost-sharing ranging from $50 to $250 after PA approval, depending on the plan. Amgen offers a co-pay card through its Repatha Now program that reduces out-of-pocket costs to as low as $0 per month for commercially insured patients who meet income criteria. That program is accessible at Amgen's website and does not require a Colorado-specific enrollment process.

Medicare Part D coverage for Repatha improved substantially after the 2023 Inflation Reduction Act drug price negotiations, but evolocumab was not among the first 10 drugs selected for direct negotiation. Part D plans continue to place Repatha on specialty tiers with cost-sharing that may reach the catastrophic coverage threshold for some patients. Medicare Supplemental (Medigap) plans do not cover Part D drugs, so the Part D plan itself determines cost-sharing.

503A Pharmacy Options in Colorado

A 503A pharmacy is a traditional compounding pharmacy regulated by the Colorado State Board of Pharmacy. Licensed 503A pharmacies compound medications for individual patients based on a valid prescription. Several Colorado-licensed 503A pharmacies hold the capability to compound preparations relevant to lipid management, though evolocumab itself, as a biologic monoclonal antibody, cannot be meaningfully reproduced through standard compounding processes. [11]

What 503A pharmacies in Colorado can provide: compounded statin formulations for patients with commercial tablet intolerance, compounded ezetimibe suspensions for patients who cannot swallow tablets, and topical or alternative-delivery forms of adjunct lipid agents. For evolocumab specifically, the FDA-approved Repatha autoinjector or prefilled syringe from Amgen remains the only available form. Patients who see advertised "compounded PCSK9 inhibitors" should verify that any such product has FDA approval, as no compounded evolocumab equivalent currently meets that bar. [1]

Transferring an Existing Repatha Prescription to Colorado

Patients relocating to Colorado with an active Repatha prescription at an out-of-state specialty pharmacy can transfer that prescription under Colorado pharmacy law, provided the prescription has refills remaining and was written by a provider licensed in the originating state at the time it was written. [12] Once you establish care with a Colorado-licensed prescriber, which Colorado insurers require within 90 to 180 days of residency, the new provider can write a fresh prescription that aligns with your Colorado plan's formulary requirements.

The specialty pharmacy transfer process involves three steps: contact your current specialty pharmacy to request an inter-pharmacy transfer to a Colorado-licensed specialty pharmacy, provide your new Colorado insurer's information (insurance card, group number, and member ID), and confirm cold-chain shipping to your Colorado address. Specialty pharmacies in the Amgen network all accommodate Colorado shipping addresses and can coordinate the transfer within 2 to 3 business days once insurance is confirmed.

One common pitfall: if your previous insurer approved the PA, that approval does not transfer to your new Colorado plan. Your new Colorado prescriber will need to submit a fresh PA to the new insurer. Getting labs updated before the transfer makes the new PA submission faster.

What to Expect After Starting Repatha

LDL-C reduction with evolocumab is measurable within 2 to 4 weeks of the first injection. [7] Most clinicians check a fasting lipid panel 4 to 8 weeks after initiation to confirm response and document the result for ongoing PA renewals. Annual PA renewals are standard across Colorado commercial plans and require an updated lipid panel showing LDL-C response.

The 140 mg every-2-week autoinjector is the most commonly prescribed formulation. The 420 mg once-monthly option uses three 140 mg injections given consecutively in the abdomen, thigh, or upper arm within 30 minutes. Both regimens produce equivalent LDL-C reduction over a 12-week period. [1] Patients who have difficulty with biweekly dosing schedules often prefer the once-monthly option for convenience.

Injection-site reactions are the most common adverse effect, reported in about 2.1% of patients in FOURIER. [7] Serious allergic reactions are rare but documented; any reaction involving hives, difficulty breathing, or facial swelling warrants immediate medical attention and discontinuation pending evaluation.

Documentation Checklist for Colorado Prior Authorization

A complete PA submission for Repatha in Colorado should include these items:

• Diagnosis code (ICD-10 E78.01 for HeFH, E78.02 for HoFH, or applicable ASCVD code such as I25.10)
• Most recent fasting LDL-C result with date of draw
• Documentation of current and prior statin names, doses, and duration of use
• Documentation of ezetimibe 10 mg trial or reason for intolerance
• Clinical notes supporting ASCVD history (catheterization report, discharge summary, imaging) if applicable
• Prescriber attestation that evolocumab is medically necessary and that background therapy has been optimized [8]

The 2018 AHA/ACC guideline statement that "for patients with very-high-risk ASCVD, use of a PCSK9 inhibitor is reasonable" [3] directly supports the medical necessity letter. Quoting this language in the PA letter, along with the FOURIER 20% relative risk reduction in the key secondary endpoint, is the combination most likely to result in first-submission approval.